PRIMARY MYELOFIBROSIS
Clinical trials for PRIMARY MYELOFIBROSIS explained in plain language.
Never miss a new study
Get alerted when new PRIMARY MYELOFIBROSIS trials appear
Sign up with your email to follow new studies for PRIMARY MYELOFIBROSIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Could a drug make stem cell transplants safer for myelofibrosis patients?
Disease control OngoingThis study tests whether giving the drug ruxolitinib before, during, and after a donor stem cell transplant can help prevent graft-versus-host disease (GVHD) in people with myelofibrosis. About 53 adults with intermediate- or high-risk myelofibrosis will receive ruxolitinib to re…
Matched conditions: PRIMARY MYELOFIBROSIS
Phase: PHASE2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated May 17, 2026 03:45 UTC
-
New hope for rare bone marrow cancer patients with dangerous low platelets
Disease control OngoingThis study tests a drug called pacritinib against standard treatments in about 400 people with myelofibrosis, a type of bone marrow cancer, who also have very low platelet counts (below 50,000). The goal is to see if pacritinib can shrink the spleen and improve symptoms like bell…
Matched conditions: PRIMARY MYELOFIBROSIS
Phase: PHASE3 • Sponsor: Swedish Orphan Biovitrum • Aim: Disease control
Last updated May 17, 2026 03:43 UTC
-
New combo aims to shrink spleens and ease symptoms in rare blood cancer
Disease control OngoingThis study tests whether adding pelabresib to the standard drug ruxolitinib works better than ruxolitinib alone for people with myelofibrosis, a rare bone marrow disorder. About 430 adults who have not had prior JAK inhibitor treatment will participate. The main goal is to see if…
Matched conditions: PRIMARY MYELOFIBROSIS
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated May 17, 2026 03:42 UTC
-
Blood disorder patients continue promising drug combo in extended safety trial
Disease control OngoingThis study looks at the long-term safety of the drugs ruxolitinib (alone or with panobinostat) in people with certain blood diseases like myelofibrosis, polycythemia vera, graft-versus-host disease, acute myeloid leukemia, or thalassemia. Participants had already been taking thes…
Matched conditions: PRIMARY MYELOFIBROSIS
Phase: PHASE4 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated May 15, 2026 11:57 UTC
-
Long-Term access to experimental drug for rare bone marrow cancer
Disease control OngoingThis study gives people with myelofibrosis, a rare bone marrow cancer, continued access to the experimental drug momelotinib. It aims to check the drug's long-term safety and see how it affects survival. Participants are already taking momelotinib in earlier studies and have not …
Matched conditions: PRIMARY MYELOFIBROSIS
Phase: PHASE2 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated May 15, 2026 11:55 UTC
-
New hope for myelofibrosis: fedratinib trial targets spleen shrinkage
Disease control OngoingThis study tests the drug fedratinib in about 31 Japanese adults with a bone marrow cancer called myelofibrosis. The goal is to see if it safely shrinks an enlarged spleen and controls the disease. Participants take the drug daily, and doctors monitor side effects and response ov…
Matched conditions: PRIMARY MYELOFIBROSIS
Phase: PHASE1, PHASE2 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated May 15, 2026 11:52 UTC
-
New hope for rare bone marrow cancer: decitabine trial shows promise
Disease control OngoingThis study tested a drug called decitabine in 21 people with myelofibrosis, a rare bone marrow cancer that causes scarring and severe anemia. The goal was to see if the drug could improve blood counts and reduce the need for transfusions. Decitabine works by reactivating genes th…
Matched conditions: PRIMARY MYELOFIBROSIS
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 14, 2026 12:03 UTC
-
New CMV strategy aims to protect stem cell transplant patients from dangerous infection
Disease control OngoingThis study looks at a modified approach to prevent and treat cytomegalovirus (CMV) infection in people who have had a donor stem cell transplant for blood cancers or disorders. About 153 participants are involved, and the goal is to see if changing when and how anti-CMV drugs are…
Matched conditions: PRIMARY MYELOFIBROSIS
Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 13, 2026 16:02 UTC
-
Could a cancer drug tame myelofibrosis?
Disease control OngoingThis study tests a drug called elotuzumab in 15 adults with a type of bone marrow cancer called myelofibrosis. The goal is to see if the drug can improve blood cell counts and bone marrow function. Participants have a specific gene mutation (JAK2) and are at intermediate or highe…
Matched conditions: PRIMARY MYELOFIBROSIS
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 12, 2026 13:43 UTC
-
Can a drug calm the chaos of myelofibrosis?
Disease control OngoingThis study tests a drug called canakinumab in people with myelofibrosis, a serious bone marrow disorder. The goal is to see if it can improve symptoms, anemia, or reduce spleen size. About 14 adults will receive injections every three weeks for 24 weeks. The study is currently ac…
Matched conditions: PRIMARY MYELOFIBROSIS
Phase: PHASE2 • Sponsor: John Mascarenhas • Aim: Disease control
Last updated May 11, 2026 20:46 UTC